Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Yuqiong Ren"'
Autor:
Yongsheng Ruan, Wei Cao, Tingting Luo, Xuan Liu, Qiujun Liu, Yuhua Xiao, Cuiling Wu, Danfeng Xie, Yuqiong Ren, Xuedong Wu, Xiaoqin Feng
Publikováno v:
Frontiers in Pediatrics, Vol 11 (2023)
Thrombocytopenia following allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a common and life-threatening complication. Thus, new prevention and treatment strategies for post-HSCT thrombocytopenia are urgently required. In recent stu
Externí odkaz:
https://doaj.org/article/2d77fffa9a3044cfb57afdb9ffa50465
Publikováno v:
Frontiers in Pediatrics, Vol 10 (2022)
BackgroundPediatric patients have significant interindividual variability in voriconazole exposure. The aim of the study was to identify factors associated with voriconazole concentrations and dose requirements to achieve therapeutic concentrations i
Externí odkaz:
https://doaj.org/article/09214e7c55c246778179faecce31dd5f
Publikováno v:
Frontiers in pediatrics. 10
Pediatric patients have significant interindividual variability in voriconazole exposure. The aim of the study was to identify factors associated with voriconazole concentrations and dose requirements to achieve therapeutic concentrations in pediatri
Autor:
Xiaodong Wang, Jianyun Wen, Xuan Liu, Wing Leung, Yuqiong Ren, Li Yu, Xiaoqin Feng, Yuelin He, Yuhua Xiao, Sixi Liu, Xiaoling Wang, Xiaoting Liu, Libai Chen, Chunfu Li, Yongsheng Ruan
Publikováno v:
Blood. 138:2875-2875
Background: For patients without HLA matched donor, Haploid stem cell transplantation with PTCY method has relatively higher risk of relapse and graft-versus-host disease (GVHD). Umbilical cord blood (UCB) is readily available and has helped expand t
Autor:
Wanxia Tan, Yuelin He, Qiujun Liu, Xuan Liu, Xiaoqin Feng, Huaying Liu, Jianyun Liao, Fuyu Pei, Xuedong Wu, Yuqiong Ren, Xiaoting Liu, Chunfu Li
Publikováno v:
Blood. 136:48-49
Background: Hematopoietic stem cell transplantation (HSCT) is the most effective curative option for patients with thalassemia major(TM). Early post-transplant mixed chimerism (MC) has known to be a predictor of secondary graft rejection. However, th
Autor:
Yongsheng Ruan, Yuqiong Ren, Wanxia Tan, Xiaoqin Feng, Jianyun Liao, Qiujun Liu, Xuan Liu, Xuedong Wu, Yuelin He, Jianyun Wen, Fuyu Pei, Chunfu Li, Xiaoting Liu
Publikováno v:
Blood. 134:3330-3330
Background: Many Chinese patients with hematologic disease, who need allogeneic hematopoietic stem cell transplantation(HSCT) commonly lack an HLA matched sibling since a Chinese family often has a single child due to Chinese one-child policy in the
Autor:
Yuqiong Ren, Na Li, Chunfu Li, Xiaoting Liu, Xuedong Wu, Goundo Sylla, Jiaqi Chen, Jianyun Liao, Yuelin He, Wing Leung, Zhiyong Peng, Fuyu Pei, Xiaoqin Feng
Publikováno v:
British journal of haematology. 179(4)
Keywords: thalasssaemia; killer-cell immunoglobulin-like receptor; haematopoietic stem cell transplantation; human leucocyte antigen; engraftment
Autor:
Yuqiong Ren, Ge Hui, Yongsheng Ruan, Xuedong Wu, Yuelin He, Liao Jianyun, Wanxia Tan, Zhiyong Peng, Xiaoqin Feng, Chunfu Li, Xiaoting Liu
Publikováno v:
Blood. 132:2082-2082
This study is to investigate the survival impact of thiotepa as part of the conditioning therapy for β thalassemia major (TM) patients, undergoing HSCT from haploidentical and sibling cord blood transplant. We retrospectively analyzed 262 transplant
Autor:
Yuelin He, Yongsheng Ruan, Yuqiong Ren, Yuhua Xiao, Xiaoqin Feng, Zhiyong Peng, Chunfu Li, Xuedong Wu
Publikováno v:
Blood. 132:2187-2187
Objective: At present allo-genetic hematopoietic stem cell transplantation (Allo-HSCT) remains the only consolidated curative approach for β- thalassemia major. How to reduce transplantation related mortality is the key to improve the curative ratio
Autor:
Shiting Liu, Xiao-qing Feng, Lei Shi, Geyu Chen, Na Li, Lan He, Fuyu Pei, Qingxia Su, Yuelin He, Huaying Liu, Qiujun Liu, Chunfu Li, Xuedong Wu, Wanxia Tan, Yanhua Wang, Yuqiong Ren, Jianyu Liao
Publikováno v:
Blood. 120(19)
We used a novel NF-08-TM transplant protocol based on intravenous busulfan, cyclophosphamide, fludarabine, and thiotepa in 82 consecutive patients with β-thalassemia major (TM), including 52 with allogeneic peripheral blood stem cell transplantation